PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients
LIVE SESSION
Topic: Acute Coronary Syndromes – Prevention
Session type: Industry Live
Date: Time:* -

See more details
Watch Replay
Chairperson
Christie Ballantyne (Houston, United States of America)
Subtitle
Sponsored by Amgen (Europe) GmbH
Learning objectives
Showcase PCSK9i mAbs from pre-clinical development to real-world data Consider the vast amount of evolocumab data across multiple indications in real-world settings Differentiate PCSK9i mAb from other therapeutic opportunities
Presentations
PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients. - Sponsored by Amgen (Europe) GmbH.
Speaker: Christie Ballantyne (Houston, United States of America), Gaetano Maria De Ferrari (Pavia, Italy), Kausik K Ray (London, United Kingdom of Great Britain & Northern Ireland), Shaun Goodman (Toronto, Canada)
Time:

PCSK9 inhibitors: from pre-clinical research to clinical practice.
Speaker: Christie Ballantyne (Houston, United States of America)
Time:

Managing patients with PCSK9 inhibitors: navigating the continuum of cardiovascular risk.
Speaker: Gaetano Maria De Ferrari (Pavia, Italy)
Time:

PCSK9 inhibitors: what can we learn from 5 years of real-world use? EU data.
Speaker: Kausik K Ray (London, United Kingdom of Great Britain & Northern Ireland)
Time:

PCSK9 inhibitors: what can we learn from 5 years of real-world use? US/Canadian data.
Speaker: Shaun Goodman (Toronto, Canada)
Time: